Parallel Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Parallel Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.82K	Buy	22 +17	+340%	+$1.36K	﹤0.01%	3538
2026 Q1	$385	Buy	+5	New	+$390	﹤0.01%	3713
2025 Q1	–	Sell	-36	Closed	-$1.99K	–	3513
2024 Q4	$1.99K	Buy	+36	New	+$2.07K	﹤0.01%	2972
2023 Q4	–	Sell	-56	Closed	-$3.25K	–	3322
2023 Q3	$3.25K	Hold	56	–	–	﹤0.01%	2654
2023 Q2	$3.01K	Hold	56	–	–	﹤0.01%	2610
2023 Q1	$2.22K	Hold	56	–	–	﹤0.01%	2735
2022 Q4	$2.25K	Sell	56 -4	-7%	-$150	﹤0.01%	2635
2022 Q3	$2K	Buy	+60	New	+$2.05K	﹤0.01%	2581
2018 Q3	–	Sell	-25	Closed	-$1K	–	2219
2018 Q2	$1K	Hold	25	–	–	﹤0.01%	1946
2018 Q1	$1K	Hold	25	–	–	﹤0.01%	1945
2017 Q4	$2K	Hold	25	–	–	﹤0.01%	1816
2017 Q3	$2K	Hold	25	–	–	﹤0.01%	1814
2017 Q2	$1K	Buy	+25	New	+$1.21K	﹤0.01%	1959

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors's ANIP Position: Q2 2026 in Review

Parallel Advisors increased its ANI Pharmaceuticals (ANIP) stake by 340% in Q2 2026, buying an estimated $1.36K and bringing the position to 22 shares worth $1.82K. The position accounts for ﹤0.01% of the portfolio, ranked #3538.

Parallel Advisors first reported a position in ANIP in Q2 2017 and has held it in 13 quarters since. The position peaked at $3.25K in Q3 2023. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Parallel Advisors held 22 shares of ANI Pharmaceuticals worth $1.82K as of Q2 2026.
Parallel Advisors bought 17 ANI Pharmaceuticals shares in Q2 2026, an estimated $1.36K.
ANI Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3538 holding.
Parallel Advisors first reported a position in ANI Pharmaceuticals in Q2 2017 and has held it in 13 quarters since.
Parallel Advisors's ANI Pharmaceuticals position peaked at $3.25K in Q3 2023.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.